Finerenone Efficacy and Safety in Patients with Chronic Kidney Disease and Glomerular DiseaseFinerenone slows kidney function loss in patients with glomerular disease

This Phase 3 randomized clinical trial evaluated the efficacy of finerenone, a non-steroidal mineralocorticoid receptor antagonist, in patients with chronic kidney disease (CKD) specifically characterized by underlying glomerular diseases. The study population included adults with an eGFR between 25 and 90 mL/min/1.73 m2 and varying levels of urinary albuminuria. This specific cohort was selected to investigate how finerenone impacts renal progression in patients whose pathology involves primary glomerular involvement.

The trial utilized a multicenter, multinational design across 24 countries. Patients were randomized to receive either 10 mg or 20 mg of finerenone daily or a matching placebo for a period of 32 months. The primary endpoint was the annualized rate of eGFR decline from baseline to month 32. Secondary endpoints included the percentage change in albuminuria at 12 months and a composite outcome involving kidney failure or a sustained 40% or greater decline in eGFR.

Results from this prespecified exploratory subgroup analysis demonstrated that finerenone significantly slowed the annual rate of eGFR decline compared to placebo. Specifically, patients receiving finerenone showed an annualized decline of -3.50 mL/min/1.73 m2 per year, whereas those on placebo experienced a steeper decline of -4.23 mL/min/1.73 m2 per year. This difference was statistically significant with a 95% confidence interval of 0.22 to 1.24.

In addition to preserving glomerular filtration rates, finerenone demonstrated a robust effect on albuminuria. At the 12-month mark, patients treated with finerenone showed a 42% reduction in albuminuria compared to the placebo group (95% CI, 35%-48%). This suggests that finerenone effectively targets the inflammatory and fibrotic pathways associated with glomerular damage.

Furthermore, the study reported a significant reduction in the risk of severe renal outcomes. The composite endpoint of kidney failure or a rapid decline in eGFR was significantly lower in the finerenone group (7.42 vs 9.60 events per 100 patient-years). The hazard ratio was 0.74, indicating a 26% reduction in the risk of reaching these critical clinical milestones.

Clinicians should note that while these results are promising for patients with glomerular disease, this specific analysis is exploratory. However, the data suggest that finerenone provides meaningful protection against the progression of chronic kidney disease and reduces markers of renal damage. The treatment appears to offer a viable pharmacological pathway for managing patients whose CKD is driven by glomerular pathology.

In conclusion, finerenone demonstrates clinical utility in slowing eGFR loss and reducing albuminuria in patients with glomerular-related CKD. These findings support its role as a targeted therapy to mitigate the progression of renal failure in this specific patient population.